ArticleJournal of acquired immune deficiency syndromes (1999)2014
Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy.
Article in Journal of acquired immune deficiency syndromes (1999), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Critical Review: When the Party is Over: A Systematic Review of Behavioral Interventions for Substance-Using Men Who Have Sex with Men.Journal of acquired immune deficiency syndromes (1999) · 2016Pooled it
- A Web-Based Antiretroviral Therapy Adherence Intervention (Thrive With Me) in a Community-Recruited Sample of Sexual Minority Men Living With HIV: Results of a Randomized Controlled Study.Journal of medical Internet research · 2024Trial
- Tina's ParTy line: Polysubstance use patterns in sexual minority men living with HIV who use methamphetamine.Drug and alcohol review · 2022Trial
- An autoregressive cross-lagged model unraveling co-occurring stimulant use and HIV: Results from a randomized controlled trial.Drug and alcohol dependence · 2021Trial
- Blue Monday: Co-occurring Stimulant Use and HIV Persistence Predict Dysregulated Catecholamine Synthesis.Journal of acquired immune deficiency syndromes (1999) · 2021Trial
- A Pilot Study of a Mobile App to Support HIV Antiretroviral Therapy Adherence Among Men Who Have Sex with Men Who Use Stimulants.AIDS and behavior · 2019Trial
- Pilot Randomized Controlled Trial of a Syndemics Intervention with HIV-Positive, Cocaine-Using Women.AIDS and behavior · 2019Trial
- Methamphetamine use drives decreases in viral suppression for people living with HIV released from a large municipal jail: Results of the LINK LA clinical trial.Drug and alcohol dependence · 2019Trial
- Randomized controlled trial of a positive affect intervention for methamphetamine users.Drug and alcohol dependence · 2018Trial
- Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection.Brain, behavior, and immunity · 2018Trial
- A community-engaged randomized controlled trial of an integrative intervention with HIV-positive, methamphetamine-using men who have sex with men.BMC public health · 2016Trial
- Longitudinal analysis of symptoms and healthcare utilization among daily cannabis-using persons living with HIV: impact of co-occurring cocaine use.Journal of cannabis research · 2026Article
- Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Optimizing an App-Based Just-in-Time Adaptive Intervention for Stimulant Use Among Sexual Minority Men Living with HIV: Protocol for a Community-Engaged Research Approach and Hybrid-Experimental Design.JMIR research protocols · 2025Article
- Outness predicts greater leukocyte telomere length in sexually minoritized men with HIV who use methamphetamine.Brain, behavior, & immunity - health · 2025Article
- Article
- Stimulant Use, HIV, and Plasma Metabolites Among Men.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Loneliness, Methamphetamine Use, and Cardiovascular Risk Factors Among Sexual Minority Men in the COVID-19 Era.International journal of behavioral medicine · 2025Article
- Challenges and Opportunities with at-Home Blood Collection for HIV-1 Viral Load Monitoring among Sexual Minoritized Men who use Stimulants.AIDS and behavior · 2024Article
- Supporting treatment adherence for resilience and thriving (START): protocol for a mHealth randomized controlled trial.BMC public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundHIV-positive persons who use stimulants (eg, methamphetamine) experience profound health disparities, but it remains unclear whether these persist after highly active antiretroviral therapy (HAART) initiation. Conducted within the Multicenter AIDS Cohort Study, this investigation examined whether stimulant use is associated with progression to AIDS or all-cause mortality after the initiation of HAART.
methodsUsing marginal structural modeling, the cumulative proportion of visits where any stimulant use was reported (ie, 0%, 1%-49%, 50%-99%, and 100%) was examined as a time-varying predictor of (1) all-cause mortality and (2) AIDS or all-cause mortality.
resultsAmong the 1313 men who have sex with men (MSM) who initiated HAART, findings showed no significant association of any level of stimulant use with all-cause mortality. A competing risk analysis indicated that no level of stimulant use was associated with increased AIDS-related or non-AIDS mortality separately. Among the 648 participants without AIDS at HAART initiation, a secondary analysis indicated that stimulant use at 50% or more of study visits was associated with a 1.5-fold increase in the odds of progression to AIDS or all-cause mortality (adjusted odds ratio = 1.54; 95% confidence interval: 1.02 to 2.33; P < 0.05).
conclusionsHIV-positive stimulant-using MSM receiving HAART seem to face no greater overall risks for all-cause, AIDS-related, or non-AIDS mortality compared with nonusers. However, men without AIDS at HAART initiation who more frequently reported stimulant use demonstrated modestly increased odds of progression to AIDS or all-cause mortality. Comprehensive approaches are needed to optimize the effectiveness of HAART with stimulant-using MSM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.